Lynx1 Capital Management LP Invests $8.61 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)

Lynx1 Capital Management LP acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 544,001 shares of the company’s stock, valued at approximately $8,612,000. Keros Therapeutics comprises about 3.2% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 8th biggest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Keros Therapeutics during the fourth quarter worth approximately $388,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics in the 4th quarter worth approximately $99,000. China Universal Asset Management Co. Ltd. raised its holdings in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock valued at $136,000 after acquiring an additional 1,372 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after purchasing an additional 1,100 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 1.5 %

NASDAQ:KROS opened at $14.21 on Friday. The firm’s fifty day simple moving average is $11.56 and its 200 day simple moving average is $27.66. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37. The firm has a market capitalization of $576.39 million, a price-to-earnings ratio of -2.73 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. On average, analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Piper Sandler decreased their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Truist Financial decreased their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.